{"ticker": {"uuid": "c6868ff4-ccfc-400d-b7bc-e09d094cfb56", "symbol": "NEO", "name": "NeoGenomics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "ETFs Investing in NeoGenomics, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold NeoGenomics, Inc. (NG9) stocks, sorted by market value. It provides detailed financial information for each ETF, including weight in the fund, issuer, management style, focus, expense ratio, assets under management", "url": "https://www.tradingview.com/symbols/GETTEX-NG9/etfs/", "source_name": "TradingView", "published_at": "2026-07-14T13:41:47", "published_display": "14 Jul 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America Securities Reaffirms Their Hold Rating on NeoGenomics (NEO)", "summary": "Bank of America Securities analyst Michael Ryskin has maintained a Hold rating on NeoGenomics (NEO) with a price target of $16.00. The company's latest earnings report showed increased quarterly revenue but a continued GAAP net loss. Analyst consensus for NeoGenomics is a Moderat", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3268973/bank-of-america-securities-reaffirms-their-hold-rating-on-neogenomics-neo/", "source_name": "The Globe and Mail", "published_at": "2026-07-14T10:41:47", "published_display": "14 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift?", "summary": "NeoGenomics recently launched PTEN IHC CDx, the first FDA-approved companion diagnostic for prostate adenocarcinoma, which helps identify patients eligible for AstraZeneca's TRUQAP. This development expands NeoGenomics' presence in urologic oncology and personalized prostate canc", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/does-neogenomics-neo-new-pten-cdx-move-reveal-a-deeper-preci", "source_name": "Simply Wall Street", "published_at": "2026-07-14T06:41:47", "published_display": "14 Jul 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics, Inc. Stock 12\u2011Month Price Target Raised to $15.67, Implies 11% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPX0YxVmx3MVhRUmVmNEJzbUhOZHo3MlQwbUt4ak9GR2RoWTNYNVM3eFA3NjRDNXpJbmR5UmhiQUxVdXlSdHZzVUt2NXBEVE9JSmYzM01SMS1jeFZRY05hX25kemtiWWtQVWxySXIyb0VhSFZnaW41NFc1bGluWmZFZUNYSGRCc1VjYVJuZkdfcWtjUm0zVWw5bzlRNTE4a1REc3g3YzZjZzAxQkhrRk4wYkFWQzlpZ0oxYUp4X3o0SDJQVzczUUZER2JMZDk4RkFSalBRTHBB?oc=5", "source_name": "TradingView", "published_at": "2026-07-13T13:20:07+00:00", "published_display": "13 Jul 2026 13:20", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NEO) Stock Trades Up, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOZ1RCT3FDZXU0Qy1LcmFqZ0dQQkJoT3hRTWpoOURnMVI3XzNiTWk0MWM5eTFYbzlsTXRnRjFieXlBS1dELUlILUVCTUlyVHVhRC0xVE51OGlaUmJBRmZLYTRnVENoNzllbFUxWVVTb3hoV2x1QUhRRWp6RHgxR20xcE5KZnowTkdEUFkzenlNY1J4VzRDbmhURVIyUjJTSmhoZXpUYmdPZw?oc=5", "source_name": "StockStory", "published_at": "2026-07-09T20:40:08+00:00", "published_display": "09 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics adds FDA-approved prostate cancer test to PanTracer Pro", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOZjY2akRLa1VhUENQbFNaZGZnOWk3b2M2Q2hFbWFUSEVjdzhCbUZwaVZhVnRVbzV2T0twOU1ReHBQLTJDZzJlQm1zbDd2TGZLUl96Qmc1ZDdoMFJ4M0tsVE83djcwNHdxWVAzbjNPMlhrZldqM0VsOGNNR19maVF4VTVyTVk4bDVtM2k2RVMzbVdTb3hPY1pvYXMwYkJfUlFrSUE5UFhCUWE4Vlh4ckI0aTF0MVU2LURDWUlnMnNvZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T11:05:00+00:00", "published_display": "09 Jul 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics launches FDA-approved prostate cancer diagnostic test", "summary": "NeoGenomics has launched PTEN IHC CDx, an FDA-approved companion diagnostic test for prostate cancer. This test identifies PTEN protein loss in patients who may benefit from AstraZeneca's TRUQAP therapy. The company has seen significant stock growth and is predicted to be profita", "url": "https://www.investing.com/news/company-news/neogenomics-launches-fdaapproved-prostate-cancer-diagnostic-test-93CH-4783691", "source_name": "Investing.com", "published_at": "2026-07-09T11:40:41", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer", "summary": "NeoGenomics, Inc. has launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma patients. This test identifies PTEN protein loss, making patients eligible for AstraZeneca's TRUQAP\u00ae therapy. It is available as a standalone ", "url": "https://www.businesswire.com/news/home/20260709775177/en/NeoGenomics-Launches-FDA-Approved-PTEN-IHC-Companion-Diagnostic-for-Prostate-Cancer", "source_name": "Business Wire", "published_at": "2026-07-09T10:40:41", "published_display": "09 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(NEO) Volatility Zones as Tactical Triggers", "summary": "This article from Stock Traders Daily discusses Neogenomics Inc. (NYSE: NEO), highlighting weak near-term sentiment but compelling upside potential without resistance levels above the current price. It outlines three AI-generated trading strategies\u2014Position Trading, Momentum Brea", "url": "https://news.stocktradersdaily.com/news_release/101/NEO_Volatility_Zones_as_Tactical_Triggers_070826115401_1783569241.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T23:54:00", "published_display": "08 Jul 2026 23:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics Inc focuses on diagnostics growth as investors watch long-term margins", "summary": "NeoGenomics Inc is a specialized diagnostics company focusing on cancer testing services, including routine pathology and advanced molecular assays. The company supports physicians, hospitals, and biopharmaceutical firms, offering services critical for treatment decisions and cli", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/neogenomics-inc-focuses-on-diagnostics-growth-as-investors-watch-long-term/69715890", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T16:13:44", "published_display": "07 Jul 2026 16:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026", "summary": "NeoGenomics, Inc. announced it will release its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026. The company will host a webcast and conference call at 4:30 p.m. ET to discuss the results and recent highlights. Interested ", "url": "https://www.biospace.com/press-releases/neogenomics-to-report-second-quarter-2026-financial-results-on-july-28-2026", "source_name": "BioSpace", "published_at": "2026-07-07T12:39:46", "published_display": "07 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics schedules July 28 results call and webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPaEkyRkxST3RTZHBkSlkwVnNRbUlVN28wenphRWdZUlZVOHdyZlc2LW1KdlE2TjYzMGYwOHJ4U2M5WXg0YWR4NjR1bGFwNFBpWlVHQ0x2b2dNcEtjZ1RqaWY3TTMycjJKV2RmR3BnZFhtcUc5c19DRnVLaWdfT0RBMzgxVjAxTXNLdWZEV2FwaE45NVRNSFBHVG1sQ2JLcVJyQzNXRHotNVZxT1dKQmh4TmM1bVJjZEZLTWZ6YVhLWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neogenomics stock hits 52-week high at 15.56 USD By Investing.com", "summary": "NeoGenomics Inc. stock recently hit a 52-week high of $15.56, indicating strong investor confidence with a 100.79% total return according to InvestingPro data. The company has also been active with financial maneuvers, including pricing $275 million in convertible senior notes, a", "url": "https://m.in.investing.com/news/stock-market-news/neogenomics-stock-hits-52week-high-at-1556-usd-93CH-5483554?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-06T21:10:37", "published_display": "06 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics on Track for Longest Winning Streak Since February 2019 -- Data Talk", "summary": "NeoGenomics (NEO) is experiencing its longest winning streak since February 2019. The company's stock has seen five consecutive days of gains. In the last year, NeoGenomics has outperformed the S&P 500, marking a positive trend for investors.", "url": "https://www.moomoo.com/news/post/72531889/neogenomics-on-track-for-longest-winning-streak-since-february-2019", "source_name": "Moomoo", "published_at": "2026-07-06T18:13:44", "published_display": "06 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEO - Neogenomics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings information for Neogenomics Inc (NEO), along with a detailed overview of its financial data, stock performance metrics, and key ratios. It includes market capitalization, income, sales, EPS, insider ownership, institutional ownership, ", "url": "https://finviz.com/stock?t=NEO&ta=1&p=d&ty=lf&r=ytd&page=3", "source_name": "Finviz", "published_at": "2026-07-06T06:10:37", "published_display": "06 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is NeoGenomics (NEO) Quietly Reframing Its Oncology Data Strategy With Starrett\u2019s Board Appointment?", "summary": "NeoGenomics (NEO) has appointed Carolyn Starrett, a former Flatiron Health CEO known for her expertise in AI and healthcare data, to its Board of Directors. This move, combined with its Epic Aura integration, suggests NeoGenomics is enhancing its oncology data strategy to differe", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/is-neogenomics-neo-quietly-reframing-its-oncology-data-strat", "source_name": "Simply Wall Street", "published_at": "2026-07-02T17:39:36", "published_display": "02 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NEO) Adds Carolyn Starrett As Its Fair Value Story Stays In Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of NeoGenomics, Inc. \u2013 NASDAQ:NEO", "summary": "This page from TradingView displays the \"Price to earnings forward\" metric for NeoGenomics, Inc. (NASDAQ: NEO). It indicates that the specific financial value for this metric is not provided directly on this overview page, showing only \"Period\", \"Value\", and \"Change %\" fields whi", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T08:09:42", "published_display": "29 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of NeoGenomics, Inc. \u2013 NASDAQ:NEO", "summary": "This article focuses on the enterprise value to EBIT forward metric for NeoGenomics, Inc. (NASDAQ: NEO). It presents financial data and analysis specific to this valuation ratio. The article is hosted on TradingView, a financial platform offering various market tools and data.", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:09:44", "published_display": "27 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics, Inc. Actuals & Estimates (NASDAQ:NEO)", "summary": "This article provides an overview of NeoGenomics, Inc. (NASDAQ: NEO) stock, covering its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's recent financial results, including earnings, revenue, and net income, along", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T16:10:41", "published_display": "27 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of NeoGenomics, Inc. \u2013 NASDAQ:NEO", "summary": "This article provides financial information for NeoGenomics, Inc. under the NASDAQ ticker NEO, specifically focusing on its enterprise value to EBITDA forward. It indicates basic financial data for the company is available through TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T16:10:41", "published_display": "27 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NeoGenomics, Inc. \u2013 NASDAQ:NEO", "summary": "This page provides financial data for NeoGenomics, Inc. (NASDAQ: NEO), specifically its price to sales forward metric. The content highlights the company's financials, news, and other relevant market information on TradingView. It appears to be a stub or a data-only content piece", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:40:18", "published_display": "27 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NeoGenomics, Inc. \u2013 NASDAQ:NEO", "summary": "This article focuses on the enterprise value to revenue forward metric for NeoGenomics, Inc. (NASDAQ: NEO). It presents financial data for the company under the NASDAQ stock market. The content primarily consists of navigational elements and data sourcing information, with the co", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:09:31", "published_display": "27 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for NeoGenomics, Inc. (NEO), based on analyst ratings and future predictions for 2027. It details the company's current stock performance, market capitalization, volatility, and addresses frequently asked questions regarding its f", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T02:10:41", "published_display": "27 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Carolyn Starrett joins NeoGenomics board of directors team", "summary": "NeoGenomics Inc. has appointed Carolyn Starrett to its board of directors. This announcement is part of a broader update on new hires and leadership appointments within various SWFL businesses. Other organizations like Collaboratory, Priority Marketing, and Capital Wealth Advisor", "url": "https://www.gulfshorebusiness.com/gb-daily/neogenomics-adds-carolyn-starrett-to-its-board-of-directors/article_3788bb02-b01c-4c6f-ab3e-52c2f47bdd0f.html", "source_name": "Gulfshore Business", "published_at": "2026-06-26T17:39:52", "published_display": "26 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NASDAQ: NEO) director receives new RSU and stock option grants", "summary": "NeoGenomics director Carolyn S. Starrett was granted 14,125 Restricted Stock Units and stock options for 9,784 shares of common stock on June 23, 2026. The stock options have an exercise price of $11.20 per share and expire on June 1, 2036. These equity awards are compensation gr", "url": "https://www.stocktitan.net/sec-filings/NEO/form-4-neogenomics-inc-insider-trading-activity-03dd049ce0a9.html", "source_name": "Stock Titan", "published_at": "2026-06-26T17:10:40", "published_display": "26 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics, Inc. Actuals & Estimates (FWB:NG9)", "summary": "This article provides an overview of NeoGenomics, Inc. (FWB:NG9) financial data and analyst estimates, including income statement, balance sheet, and cash flow information. It details stock performance, analyst price targets, and key financial metrics like earnings per share, rev", "url": "https://www.tradingview.com/symbols/FWB-NG9/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:40:18", "published_display": "26 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics, Inc. Actuals & Estimates (DUS:NG9)", "summary": "This article provides financial actuals and estimates for NeoGenomics, Inc. (NG9) on the Dusseldorf Stock Exchange. It covers income statement, balance sheet, cash flow, and valuation metrics, along with analyst price targets. Key information includes a max price estimate of 21.2", "url": "https://www.tradingview.com/symbols/DUS-NG9/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:52", "published_display": "26 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NEO) director Carolyn Starrett files initial Form 3", "summary": "NeoGenomics (NEO) director Carolyn Starrett has filed an initial Form 3 with the SEC, indicating her new status as a reporting insider for the company. The filing shows no transactions or holdings at this time, serving as an initial disclosure of beneficial ownership. This transp", "url": "https://www.stocktitan.net/sec-filings/NEO/form-3-neogenomics-inc-initial-statement-of-beneficial-ownership-05eedc1b6684.html", "source_name": "Stock Titan", "published_at": "2026-06-26T07:10:41", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Testing & Diagnostics Services Stocks\u2019 Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack", "summary": "This article reviews the Q1 earnings of several testing and diagnostics services stocks, highlighting NeoGenomics (NEO), Guardant Health (GH), RadNet (RDNT), Labcorp (LH), and Quest Diagnostics (DGX). It notes that the industry as a whole reported strong Q1 results, with revenues", "url": "https://www.tradingview.com/news/stockstory:ce08ecaba094b:0-a-look-back-at-testing-diagnostics-services-stocks-q1-earnings-neogenomics-nasdaq-neo-vs-the-rest-of-the-pack/", "source_name": "TradingView", "published_at": "2026-06-26T03:39:52", "published_display": "26 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics Appoints Carolyn Starrett to its Board of Directors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neogenomics-appoints-carolyn-starrett-board-110500004.html", "source_name": "Business Wire", "published_at": "2026-06-25T11:05:00+00:00", "published_display": "25 Jun 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics taps Flatiron ex-CEO Carolyn Starrett for its board", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNZFJRczdiYVZuQ1R4dTZ6ZHJ6aXZZWlhJWkk1MS1SbUhlbC1pRmtKY2EybEo3X1JXMmRhRkZqRE1mNlNPR0cxeFhmMzZHM3JUa1h1SFFvZGlzUnhScUg4ejRFLU9oWjktemJXc3h5dHp2RUROcml2TzA0Y0owTEQxVFY5YUxsOXJtUElxMG1nRHJSQVNnbTJDQktlT1JXVWM4Q1lmQjRqV3RPZG5M?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NASDAQ: NEO) sells $316M converts, refinances 2028 notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNZW9aMUhQMEppQkVWajNSeXJnVWxHMm96VGJhWEhjSHN2Rks4RFBjeXNxVVE1SkloU2VBcWxjcnh0ODEyVzlsWEthV1FoalNKU01xUVpUM2FqZ0NqUVljTUtoUTlDdUoteTYxaXptOFlrYnI5QlJtMkxoQ1RvSW50bjk2S0VMb2ZfVXVvMXhlWk83ejI3T1MyOE9rdlk0TW9rU0RaMVdB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNQnpsNTBNRnJIc2FQTDhLeFNTMDJyYkk5MGRkdGVYOXBoR3A1Umh3eFlwRUJZZ3VHTXlsNjQ5ZFlLZWdjTzZhM0NJVEw3SjFVdEl4Qm9QSGQtUkdzRk9GRVpaZDk5b0xpQlRVbDVmRmFscmhIaTV4cG1saEJXM3Ezd3JNZ1FGTW1VMnJWeGI4dFFDNkEx?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics\u2019s (NASDAQ:NEO) Q1 CY2026: Beats On Revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQnoybGxNRGR6ZXpwWEN3LTl1dGlzN0JEZXJjRkpFYnQ4dFl3M2ZwSjFSMmkzX25SNDc4cnZRTjlDc1ZSVGUxNXd2cXNENGhPZ01hT3RBOEpjQWRvR3hMUl9qTHFvc1ZiSjZYdEpqZENydUJfdmppVU8wWHExVno1YmdibVVObWJVZXdSS0ZtRzBvTGlMYzI3bG1sdmM4dGdiNnRtRldIdFFhMVU?oc=5", "source_name": "StockStory", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why NeoGenomics (NEO) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNc0pGTkYzeTNKbjVxVnoyQUljYXBJV3k4OUcyazcteEw1VUhERU9GQkdoNkZUd0FxX3h3Vl9jMkxwcFlVU3owQlJMSWF0QlJMcS1yZHZ6b2JacFc2dHUwcnZmcWY1aUFuRHRQbVhvN2Q0S3U5VEFBVUN4MzlmZkhQTlE1clpHeEtyWHlPZ3JzM213QzF1Yks5LUhTVGM3Ukk?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Testing & Diagnostics Services Stocks\u2019 Q4 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRktHQjBiMVdqWlJpblE1UUQwcEsxUzRiaUw0UC0zMHlYXzkzTDU1TEtGMnVmOUVmd25LV1NxVVJyUGVqSzhCQTQtV0JNYXFvMk11eU05TW5mTXQ3Y2FKbnlyZzluY3h1czZSTVRLZWlONE55dUJacHROZ0tkM3RsbWNMT09sa1lON0RIajFITEsxWWZ1ZjlZTTFVZXdkQ3E3YTFrYnpEZDlvN00?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why NeoGenomics (NEO) Shares Are Falling Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNNFlQdTJrWWxVcGR1YkRwR1dxQ3NrU0hHbGl1UGR6VUhNamk2QkNsdDJqSFF4S0x1U0NpRVkxZlpJazRTejFXWlFXTlRnN20tb05Kd0dFWjhtSndUNXFMNU1fWGFMd2w1OGNId2ZKTmhXazJ0UDVDZW1NR0x2aF9QSkdFaFhyTU0?oc=5", "source_name": "Market source", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics PanTracer Pro Launch Sets New Test Against Weak Share Performance", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Don't Ignore The Insider Selling In NeoGenomics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNVU1PNkN4M1BDd0c3MWNwdmVLd2pHT3N6UUI5RE5GbWJwaHlzRlA2R3NBc21rMHRnMTVEQTJOck1uMnRPRnhmd2IxUERUYUVpdVF2MUZJRjdlTVdKR0tLNmREelJfV2R4YTJpempXQmt2Ym5pdWZBOUotNHpjeC1zRFljc1dzRHFETzRyVDdZMGdwSVZPV1EyYzlXSHRVVHJ3cWpyRXhHZkF5VUtpVmNCbnpSWUxobFBQ0gG-AUFVX3lxTE5DNmJiLWZEY01kbXZVamVIU1JNQldlcTVOYzZ6UE1YcHFjeWN2YTNYNjFPcnNaNmoybklGbTFXb1ZMTWRoWi1rM1kweS03Q3VlNm12VlRfTklrYzMxRE5TbnVXSzhybktYcWNnUjU5ZFFaLWFWYlQ1aUQ5d2k5UXVvSUUzcnlXczQ5cEFzNXQ5VHFSMDhUcWdSU21GZ0RzaVlFaFRZVmgyZTRBNWtJcmJMNFU3bUtiRmNnb1ZGX0E?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-27T07:00:00+00:00", "published_display": "27 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NASDAQ:NEO investor five-year losses grow to 81% as the stock sheds US$71m this past week", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNRnVnM3dERi03V2NWbVFjM196M1kyZDRWcVM5SnRpeEZBYWNmdWkxZmZsMHNSdl90TV9XaWYxaTlOUFJETW5aZzJxREppWTZGOXRRaFdXRHh3dFNTd0VrVWlINGRzSXJmczhfekpqbVJLMjV3ZkhqRFpPNjFYQ2c5bUtScHV2ZW9EYS1LMllYelNyTmlWU1VKdTkzejFCNUtGa1FlUWxIdHFaUF95VDFINUc3blBNWHdwcEp5Qy02OW5RM3V5SlQxLWtIVdIB0AFBVV95cUxONlhzNDBxT2UtT19JNUhhQlRKY3RoakhnTHJBQ0doNzZxYzVrOUh1dHc0WFpYRERkclI0UFBnN0Z2NHZTUnU1YTdSVWNxQzV5RlpjSmVhUGdXcDY2T2dsMGx2NlY2SktrWW04SG0zb2pTTG8yandkNHFYTmVJOUNwbEx3M2pjTmNCQVhvNjhwX0VZZHBDeTk3UjFRczdpZmFXQXExcVVPdndnUnVIVktmY2JnbDAyeTU5VmZnclltOG9tcXpaTzF1aXFZOHMzRU1q?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-16T07:00:00+00:00", "published_display": "16 Jul 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics Q3 Revenue Surges 10% to $168M, Boosts 2024 EBITDA Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQRlpPam5Fa2lndEZ6LVdRdGdUc2FDdXE4bFdHSExSUlJOS1dZTGNoVGNwTGJmUmpIMDc1dk5FRmpUdE9CU3lHMWJSNmRyQ2tQQTNjcHI1UURYZWIxcXZqX3FOYlFQcm5XMm9Sb0k2M1BHZm93RjJud3BqVFdVa0FPbUJVZGozUzdIT3NYT04xX1ZaQVFZU0M3VQ?oc=5", "source_name": "Stock Titan", "published_at": "2024-11-05T08:00:00+00:00", "published_display": "05 Nov 2024 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ETFs Investing in NeoGenomics, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold NeoGenomics, Inc. (NG9) stocks, sorted by market value. It provides detailed financial information for each ETF, including weight in the fund, issuer, management style, focus, expense ratio, assets under management", "url": "https://www.tradingview.com/symbols/GETTEX-NG9/etfs/", "source_name": "TradingView", "published_at": "2026-07-14T13:41:47", "published_display": "14 Jul 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of America Securities Reaffirms Their Hold Rating on NeoGenomics (NEO)", "summary": "Bank of America Securities analyst Michael Ryskin has maintained a Hold rating on NeoGenomics (NEO) with a price target of $16.00. The company's latest earnings report showed increased quarterly revenue but a continued GAAP net loss. Analyst consensus for NeoGenomics is a Moderat", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3268973/bank-of-america-securities-reaffirms-their-hold-rating-on-neogenomics-neo/", "source_name": "The Globe and Mail", "published_at": "2026-07-14T10:41:47", "published_display": "14 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does NeoGenomics (NEO) New PTEN CDx Move Reveal a Deeper Precision Oncology Strategy Shift?", "summary": "NeoGenomics recently launched PTEN IHC CDx, the first FDA-approved companion diagnostic for prostate adenocarcinoma, which helps identify patients eligible for AstraZeneca's TRUQAP. This development expands NeoGenomics' presence in urologic oncology and personalized prostate canc", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/does-neogenomics-neo-new-pten-cdx-move-reveal-a-deeper-preci", "source_name": "Simply Wall Street", "published_at": "2026-07-14T06:41:47", "published_display": "14 Jul 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics, Inc. Stock 12\u2011Month Price Target Raised to $15.67, Implies 11% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPX0YxVmx3MVhRUmVmNEJzbUhOZHo3MlQwbUt4ak9GR2RoWTNYNVM3eFA3NjRDNXpJbmR5UmhiQUxVdXlSdHZzVUt2NXBEVE9JSmYzM01SMS1jeFZRY05hX25kemtiWWtQVWxySXIyb0VhSFZnaW41NFc1bGluWmZFZUNYSGRCc1VjYVJuZkdfcWtjUm0zVWw5bzlRNTE4a1REc3g3YzZjZzAxQkhrRk4wYkFWQzlpZ0oxYUp4X3o0SDJQVzczUUZER2JMZDk4RkFSalBRTHBB?oc=5", "source_name": "TradingView", "published_at": "2026-07-13T13:20:07+00:00", "published_display": "13 Jul 2026 13:20", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NEO) Stock Trades Up, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOZ1RCT3FDZXU0Qy1LcmFqZ0dQQkJoT3hRTWpoOURnMVI3XzNiTWk0MWM5eTFYbzlsTXRnRjFieXlBS1dELUlILUVCTUlyVHVhRC0xVE51OGlaUmJBRmZLYTRnVENoNzllbFUxWVVTb3hoV2x1QUhRRWp6RHgxR20xcE5KZnowTkdEUFkzenlNY1J4VzRDbmhURVIyUjJTSmhoZXpUYmdPZw?oc=5", "source_name": "StockStory", "published_at": "2026-07-09T20:40:08+00:00", "published_display": "09 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics adds FDA-approved prostate cancer test to PanTracer Pro", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOZjY2akRLa1VhUENQbFNaZGZnOWk3b2M2Q2hFbWFUSEVjdzhCbUZwaVZhVnRVbzV2T0twOU1ReHBQLTJDZzJlQm1zbDd2TGZLUl96Qmc1ZDdoMFJ4M0tsVE83djcwNHdxWVAzbjNPMlhrZldqM0VsOGNNR19maVF4VTVyTVk4bDVtM2k2RVMzbVdTb3hPY1pvYXMwYkJfUlFrSUE5UFhCUWE4Vlh4ckI0aTF0MVU2LURDWUlnMnNvZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T11:05:00+00:00", "published_display": "09 Jul 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics launches FDA-approved prostate cancer diagnostic test", "summary": "NeoGenomics has launched PTEN IHC CDx, an FDA-approved companion diagnostic test for prostate cancer. This test identifies PTEN protein loss in patients who may benefit from AstraZeneca's TRUQAP therapy. The company has seen significant stock growth and is predicted to be profita", "url": "https://www.investing.com/news/company-news/neogenomics-launches-fdaapproved-prostate-cancer-diagnostic-test-93CH-4783691", "source_name": "Investing.com", "published_at": "2026-07-09T11:40:41", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer", "summary": "NeoGenomics, Inc. has launched PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma patients. This test identifies PTEN protein loss, making patients eligible for AstraZeneca's TRUQAP\u00ae therapy. It is available as a standalone ", "url": "https://www.businesswire.com/news/home/20260709775177/en/NeoGenomics-Launches-FDA-Approved-PTEN-IHC-Companion-Diagnostic-for-Prostate-Cancer", "source_name": "Business Wire", "published_at": "2026-07-09T10:40:41", "published_display": "09 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(NEO) Volatility Zones as Tactical Triggers", "summary": "This article from Stock Traders Daily discusses Neogenomics Inc. (NYSE: NEO), highlighting weak near-term sentiment but compelling upside potential without resistance levels above the current price. It outlines three AI-generated trading strategies\u2014Position Trading, Momentum Brea", "url": "https://news.stocktradersdaily.com/news_release/101/NEO_Volatility_Zones_as_Tactical_Triggers_070826115401_1783569241.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-08T23:54:00", "published_display": "08 Jul 2026 23:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics Inc focuses on diagnostics growth as investors watch long-term margins", "summary": "NeoGenomics Inc is a specialized diagnostics company focusing on cancer testing services, including routine pathology and advanced molecular assays. The company supports physicians, hospitals, and biopharmaceutical firms, offering services critical for treatment decisions and cli", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/neogenomics-inc-focuses-on-diagnostics-growth-as-investors-watch-long-term/69715890", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T16:13:44", "published_display": "07 Jul 2026 16:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026", "summary": "NeoGenomics, Inc. announced it will release its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026. The company will host a webcast and conference call at 4:30 p.m. ET to discuss the results and recent highlights. Interested ", "url": "https://www.biospace.com/press-releases/neogenomics-to-report-second-quarter-2026-financial-results-on-july-28-2026", "source_name": "BioSpace", "published_at": "2026-07-07T12:39:46", "published_display": "07 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics schedules July 28 results call and webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPaEkyRkxST3RTZHBkSlkwVnNRbUlVN28wenphRWdZUlZVOHdyZlc2LW1KdlE2TjYzMGYwOHJ4U2M5WXg0YWR4NjR1bGFwNFBpWlVHQ0x2b2dNcEtjZ1RqaWY3TTMycjJKV2RmR3BnZFhtcUc5c19DRnVLaWdfT0RBMzgxVjAxTXNLdWZEV2FwaE45NVRNSFBHVG1sQ2JLcVJyQzNXRHotNVZxT1dKQmh4TmM1bVJjZEZLTWZ6YVhLWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neogenomics stock hits 52-week high at 15.56 USD By Investing.com", "summary": "NeoGenomics Inc. stock recently hit a 52-week high of $15.56, indicating strong investor confidence with a 100.79% total return according to InvestingPro data. The company has also been active with financial maneuvers, including pricing $275 million in convertible senior notes, a", "url": "https://m.in.investing.com/news/stock-market-news/neogenomics-stock-hits-52week-high-at-1556-usd-93CH-5483554?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-06T21:10:37", "published_display": "06 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics on Track for Longest Winning Streak Since February 2019 -- Data Talk", "summary": "NeoGenomics (NEO) is experiencing its longest winning streak since February 2019. The company's stock has seen five consecutive days of gains. In the last year, NeoGenomics has outperformed the S&P 500, marking a positive trend for investors.", "url": "https://www.moomoo.com/news/post/72531889/neogenomics-on-track-for-longest-winning-streak-since-february-2019", "source_name": "Moomoo", "published_at": "2026-07-06T18:13:44", "published_display": "06 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEO - Neogenomics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings information for Neogenomics Inc (NEO), along with a detailed overview of its financial data, stock performance metrics, and key ratios. It includes market capitalization, income, sales, EPS, insider ownership, institutional ownership, ", "url": "https://finviz.com/stock?t=NEO&ta=1&p=d&ty=lf&r=ytd&page=3", "source_name": "Finviz", "published_at": "2026-07-06T06:10:37", "published_display": "06 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is NeoGenomics (NEO) Quietly Reframing Its Oncology Data Strategy With Starrett\u2019s Board Appointment?", "summary": "NeoGenomics (NEO) has appointed Carolyn Starrett, a former Flatiron Health CEO known for her expertise in AI and healthcare data, to its Board of Directors. This move, combined with its Epic Aura integration, suggests NeoGenomics is enhancing its oncology data strategy to differe", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/is-neogenomics-neo-quietly-reframing-its-oncology-data-strat", "source_name": "Simply Wall Street", "published_at": "2026-07-02T17:39:36", "published_display": "02 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NEO) Adds Carolyn Starrett As Its Fair Value Story Stays In Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of NeoGenomics, Inc. \u2013 NASDAQ:NEO", "summary": "This page from TradingView displays the \"Price to earnings forward\" metric for NeoGenomics, Inc. (NASDAQ: NEO). It indicates that the specific financial value for this metric is not provided directly on this overview page, showing only \"Period\", \"Value\", and \"Change %\" fields whi", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T08:09:42", "published_display": "29 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of NeoGenomics, Inc. \u2013 NASDAQ:NEO", "summary": "This article focuses on the enterprise value to EBIT forward metric for NeoGenomics, Inc. (NASDAQ: NEO). It presents financial data and analysis specific to this valuation ratio. The article is hosted on TradingView, a financial platform offering various market tools and data.", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:09:44", "published_display": "27 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics, Inc. Actuals & Estimates (NASDAQ:NEO)", "summary": "This article provides an overview of NeoGenomics, Inc. (NASDAQ: NEO) stock, covering its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's recent financial results, including earnings, revenue, and net income, along", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T16:10:41", "published_display": "27 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of NeoGenomics, Inc. \u2013 NASDAQ:NEO", "summary": "This article provides financial information for NeoGenomics, Inc. under the NASDAQ ticker NEO, specifically focusing on its enterprise value to EBITDA forward. It indicates basic financial data for the company is available through TradingView.", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T16:10:41", "published_display": "27 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NeoGenomics, Inc. \u2013 NASDAQ:NEO", "summary": "This page provides financial data for NeoGenomics, Inc. (NASDAQ: NEO), specifically its price to sales forward metric. The content highlights the company's financials, news, and other relevant market information on TradingView. It appears to be a stub or a data-only content piece", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T11:40:18", "published_display": "27 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NeoGenomics, Inc. \u2013 NASDAQ:NEO", "summary": "This article focuses on the enterprise value to revenue forward metric for NeoGenomics, Inc. (NASDAQ: NEO). It presents financial data for the company under the NASDAQ stock market. The content primarily consists of navigational elements and data sourcing information, with the co", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:09:31", "published_display": "27 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for NeoGenomics, Inc. (NEO), based on analyst ratings and future predictions for 2027. It details the company's current stock performance, market capitalization, volatility, and addresses frequently asked questions regarding its f", "url": "https://www.tradingview.com/symbols/NASDAQ-NEO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T02:10:41", "published_display": "27 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Carolyn Starrett joins NeoGenomics board of directors team", "summary": "NeoGenomics Inc. has appointed Carolyn Starrett to its board of directors. This announcement is part of a broader update on new hires and leadership appointments within various SWFL businesses. Other organizations like Collaboratory, Priority Marketing, and Capital Wealth Advisor", "url": "https://www.gulfshorebusiness.com/gb-daily/neogenomics-adds-carolyn-starrett-to-its-board-of-directors/article_3788bb02-b01c-4c6f-ab3e-52c2f47bdd0f.html", "source_name": "Gulfshore Business", "published_at": "2026-06-26T17:39:52", "published_display": "26 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 59, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NASDAQ: NEO) director receives new RSU and stock option grants", "summary": "NeoGenomics director Carolyn S. Starrett was granted 14,125 Restricted Stock Units and stock options for 9,784 shares of common stock on June 23, 2026. The stock options have an exercise price of $11.20 per share and expire on June 1, 2036. These equity awards are compensation gr", "url": "https://www.stocktitan.net/sec-filings/NEO/form-4-neogenomics-inc-insider-trading-activity-03dd049ce0a9.html", "source_name": "Stock Titan", "published_at": "2026-06-26T17:10:40", "published_display": "26 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics, Inc. Actuals & Estimates (FWB:NG9)", "summary": "This article provides an overview of NeoGenomics, Inc. (FWB:NG9) financial data and analyst estimates, including income statement, balance sheet, and cash flow information. It details stock performance, analyst price targets, and key financial metrics like earnings per share, rev", "url": "https://www.tradingview.com/symbols/FWB-NG9/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T13:40:18", "published_display": "26 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics, Inc. Actuals & Estimates (DUS:NG9)", "summary": "This article provides financial actuals and estimates for NeoGenomics, Inc. (NG9) on the Dusseldorf Stock Exchange. It covers income statement, balance sheet, cash flow, and valuation metrics, along with analyst price targets. Key information includes a max price estimate of 21.2", "url": "https://www.tradingview.com/symbols/DUS-NG9/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:39:52", "published_display": "26 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NEO) director Carolyn Starrett files initial Form 3", "summary": "NeoGenomics (NEO) director Carolyn Starrett has filed an initial Form 3 with the SEC, indicating her new status as a reporting insider for the company. The filing shows no transactions or holdings at this time, serving as an initial disclosure of beneficial ownership. This transp", "url": "https://www.stocktitan.net/sec-filings/NEO/form-3-neogenomics-inc-initial-statement-of-beneficial-ownership-05eedc1b6684.html", "source_name": "Stock Titan", "published_at": "2026-06-26T07:10:41", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Testing & Diagnostics Services Stocks\u2019 Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack", "summary": "This article reviews the Q1 earnings of several testing and diagnostics services stocks, highlighting NeoGenomics (NEO), Guardant Health (GH), RadNet (RDNT), Labcorp (LH), and Quest Diagnostics (DGX). It notes that the industry as a whole reported strong Q1 results, with revenues", "url": "https://www.tradingview.com/news/stockstory:ce08ecaba094b:0-a-look-back-at-testing-diagnostics-services-stocks-q1-earnings-neogenomics-nasdaq-neo-vs-the-rest-of-the-pack/", "source_name": "TradingView", "published_at": "2026-06-26T03:39:52", "published_display": "26 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics Appoints Carolyn Starrett to its Board of Directors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neogenomics-appoints-carolyn-starrett-board-110500004.html", "source_name": "Business Wire", "published_at": "2026-06-25T11:05:00+00:00", "published_display": "25 Jun 2026 11:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics taps Flatiron ex-CEO Carolyn Starrett for its board", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNZFJRczdiYVZuQ1R4dTZ6ZHJ6aXZZWlhJWkk1MS1SbUhlbC1pRmtKY2EybEo3X1JXMmRhRkZqRE1mNlNPR0cxeFhmMzZHM3JUa1h1SFFvZGlzUnhScUg4ejRFLU9oWjktemJXc3h5dHp2RUROcml2TzA0Y0owTEQxVFY5YUxsOXJtUElxMG1nRHJSQVNnbTJDQktlT1JXVWM4Q1lmQjRqV3RPZG5M?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NASDAQ: NEO) sells $316M converts, refinances 2028 notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNZW9aMUhQMEppQkVWajNSeXJnVWxHMm96VGJhWEhjSHN2Rks4RFBjeXNxVVE1SkloU2VBcWxjcnh0ODEyVzlsWEthV1FoalNKU01xUVpUM2FqZ0NqUVljTUtoUTlDdUoteTYxaXptOFlrYnI5QlJtMkxoQ1RvSW50bjk2S0VMb2ZfVXVvMXhlWk83ejI3T1MyOE9rdlk0TW9rU0RaMVdB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNQnpsNTBNRnJIc2FQTDhLeFNTMDJyYkk5MGRkdGVYOXBoR3A1Umh3eFlwRUJZZ3VHTXlsNjQ5ZFlLZWdjTzZhM0NJVEw3SjFVdEl4Qm9QSGQtUkdzRk9GRVpaZDk5b0xpQlRVbDVmRmFscmhIaTV4cG1saEJXM3Ezd3JNZ1FGTW1VMnJWeGI4dFFDNkEx?oc=5", "source_name": "Market source", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics\u2019s (NASDAQ:NEO) Q1 CY2026: Beats On Revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQnoybGxNRGR6ZXpwWEN3LTl1dGlzN0JEZXJjRkpFYnQ4dFl3M2ZwSjFSMmkzX25SNDc4cnZRTjlDc1ZSVGUxNXd2cXNENGhPZ01hT3RBOEpjQWRvR3hMUl9qTHFvc1ZiSjZYdEpqZENydUJfdmppVU8wWHExVno1YmdibVVObWJVZXdSS0ZtRzBvTGlMYzI3bG1sdmM4dGdiNnRtRldIdFFhMVU?oc=5", "source_name": "StockStory", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why NeoGenomics (NEO) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNc0pGTkYzeTNKbjVxVnoyQUljYXBJV3k4OUcyazcteEw1VUhERU9GQkdoNkZUd0FxX3h3Vl9jMkxwcFlVU3owQlJMSWF0QlJMcS1yZHZ6b2JacFc2dHUwcnZmcWY1aUFuRHRQbVhvN2Q0S3U5VEFBVUN4MzlmZkhQTlE1clpHeEtyWHlPZ3JzM213QzF1Yks5LUhTVGM3Ukk?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Testing & Diagnostics Services Stocks\u2019 Q4 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRktHQjBiMVdqWlJpblE1UUQwcEsxUzRiaUw0UC0zMHlYXzkzTDU1TEtGMnVmOUVmd25LV1NxVVJyUGVqSzhCQTQtV0JNYXFvMk11eU05TW5mTXQ3Y2FKbnlyZzluY3h1czZSTVRLZWlONE55dUJacHROZ0tkM3RsbWNMT09sa1lON0RIajFITEsxWWZ1ZjlZTTFVZXdkQ3E3YTFrYnpEZDlvN00?oc=5", "source_name": "Market source", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why NeoGenomics (NEO) Shares Are Falling Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNNFlQdTJrWWxVcGR1YkRwR1dxQ3NrU0hHbGl1UGR6VUhNamk2QkNsdDJqSFF4S0x1U0NpRVkxZlpJazRTejFXWlFXTlRnN20tb05Kd0dFWjhtSndUNXFMNU1fWGFMd2w1OGNId2ZKTmhXazJ0UDVDZW1NR0x2aF9QSkdFaFhyTU0?oc=5", "source_name": "Market source", "published_at": "2026-02-18T08:00:00+00:00", "published_display": "18 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics PanTracer Pro Launch Sets New Test Against Weak Share Performance", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-15T08:00:00+00:00", "published_display": "15 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Don't Ignore The Insider Selling In NeoGenomics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNVU1PNkN4M1BDd0c3MWNwdmVLd2pHT3N6UUI5RE5GbWJwaHlzRlA2R3NBc21rMHRnMTVEQTJOck1uMnRPRnhmd2IxUERUYUVpdVF2MUZJRjdlTVdKR0tLNmREelJfV2R4YTJpempXQmt2Ym5pdWZBOUotNHpjeC1zRFljc1dzRHFETzRyVDdZMGdwSVZPV1EyYzlXSHRVVHJ3cWpyRXhHZkF5VUtpVmNCbnpSWUxobFBQ0gG-AUFVX3lxTE5DNmJiLWZEY01kbXZVamVIU1JNQldlcTVOYzZ6UE1YcHFjeWN2YTNYNjFPcnNaNmoybklGbTFXb1ZMTWRoWi1rM1kweS03Q3VlNm12VlRfTklrYzMxRE5TbnVXSzhybktYcWNnUjU5ZFFaLWFWYlQ1aUQ5d2k5UXVvSUUzcnlXczQ5cEFzNXQ5VHFSMDhUcWdSU21GZ0RzaVlFaFRZVmgyZTRBNWtJcmJMNFU3bUtiRmNnb1ZGX0E?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-27T07:00:00+00:00", "published_display": "27 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics (NASDAQ:NEO investor five-year losses grow to 81% as the stock sheds US$71m this past week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-16T07:00:00+00:00", "published_display": "16 Jul 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NeoGenomics Q3 Revenue Surges 10% to $168M, Boosts 2024 EBITDA Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQRlpPam5Fa2lndEZ6LVdRdGdUc2FDdXE4bFdHSExSUlJOS1dZTGNoVGNwTGJmUmpIMDc1dk5FRmpUdE9CU3lHMWJSNmRyQ2tQQTNjcHI1UURYZWIxcXZqX3FOYlFQcm5XMm9Sb0k2M1BHZm93RjJud3BqVFdVa0FPbUJVZGozUzdIT3NYT04xX1ZaQVFZU0M3VQ?oc=5", "source_name": "Stock Titan", "published_at": "2024-11-05T08:00:00+00:00", "published_display": "05 Nov 2024 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 102, "total_relevant": 43, "sentiment_summary": {"positive": 13, "negative": 2, "neutral": 28, "score": 56, "total": 43, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 14.85, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 11}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 14.11, "latest_week": "2026-07-10", "one_week_move": -6.9, "four_week_move": 26.5, "twelve_week_move": 69.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.302047, "market_dynamics_buy_signal": false, "relative_strength": 24.157386, "fair_value_gap": 12.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 43.578, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.9% over one week, +26.5% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Stock Titan", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "Market source", "count": 4}, {"label": "Simply Wall Street", "count": 2}, {"label": "StockStory", "count": 2}, {"label": "Business Wire", "count": 2}, {"label": "The Globe and Mail", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 11}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.9% over one week, +26.5% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ETFs Investing in NeoGenomics, Inc. Stocks"}], "updated_at": "2026-07-16T08:06:34.703436+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}